28218-71-5

Usage

Uses

Used in the Food Industry:
4,4-Dimethoxy-tetrahydro-4H-pyran is used as a flavor and scent enhancer for various food products. Its ability to improve the taste and aroma of food items makes it a valuable ingredient in the culinary world.
Used in Chemical Reactions:
In laboratories and industries, 4,4-Dimethoxy-tetrahydro-4H-pyran is used as a reactant in numerous chemical reactions. Its unique properties make it a versatile compound for various applications, contributing to the synthesis of different products and materials.
Safety Precautions:
Due to its potential hazards, 4,4-Dimethoxy-tetrahydro-4H-pyran should be handled with caution. It is essential to follow safety protocols and control measures to minimize the risk of irritation to the eyes, skin, and respiratory system. Proper protective equipment and controlled conditions are necessary when working with 4,4-DIMETHOXY-TETRAHYDRO-4H-PYRAN.

InChI:InChI=1/C7H14O3/c1-8-7(9-2)3-5-10-6-4-7/h3-6H2,1-2H3

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 67-56-1 methanol 
• 149-73-5 trimethyl orthoformate 
• 77-76-9 2,2-dimethoxy-propane 

Downstream Products

• 17327-22-9 4-methoxy-2,6-dihydropyran 
• 624734-19-6 3-fluorodihydro-2H-pyran-4(3H)-one 
• 1630906-37-4 (3R,4R)-3-fluorotetrahydro-2H-pyran-4-amine hydrochloride 
• 1395080-72-4 (3R,4R)-N-benzyl-3-fluorotetrahydro-2H-pyran-4-amine 
• 1630906-37-4 (3S,4S)-3-fluorotetrahydro-2H-pyran-4-amine hydrochloride 
• 1395080-71-3 (3R,4R)-N-benzyl-3-fluorotetrahydro-2H-pyran-4-amine 
• 1270077-00-3 6-(benzyloxy)-3-fluoro-N-((4-methoxytetrahydro-2H-pyran-4-yl)methyl)pyridin-2-amine 
• 1269755-10-3 (4-methoxytetrahydro-2H-pyran-4-yl)methanamine 
• 175982-78-2 1-(4-Methoxy-tetrahydro-pyran-4-yl)-ethanone 
• 175982-76-0 4-methoxytetrahydro-2H-pyran-4-carbaldehyde 

Relevant academic research and scientific papers

Synthesis of Functionalized Aliphatic Acid Esters via the Generation of Alkyl Radicals from Silylperoxyacetals

We describe a catalytic method for the synthesis of a variety of functionalized aliphatic acid esters using silylperoxyacetals, which are versatile alkyl radical precursors with a terminal ester moiety. In the presence of an appropriate transition-metal catalyst, the in situ generation of alkyl radicals and the subsequent bond-forming process proceeds smoothly to afford synthetically valuable aliphatic acid derivatives. The present method can be applied to the efficient synthesis of a pharmaceutically important 1,1-diarylalkane motif. In addition, a novel strategy for the synthesis of structurally diverse hydroxy acid derivatives via a C?O bond formation process that utilizes TEMPO has been developed.

SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds

3-(AMINOARYL)-PYRIDINE COMPOUNDS

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

HETEROARYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor